ERBB2 and gallbladder cancer: The incidence of HER2 overexpressing disease in this study is consistent with previous reports showing 18%, 8% and 27% of patients with gallbladder cancer, intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, respectively.